Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer

Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses the KEYNOTE-826 trial (NCT03635567), a Phase III study assessing the efficacy and safety of pembrolizumab plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.